Michael R Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael R Lee has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- William Ryman
Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
3 shared publications Alan J Cooper
Department of Dermatology, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, Australia
2 shared publicationsGayle O Fischer
Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publicationLi‐Chuen F Wong
Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publicationStephen Shumack
Department of Dermatology, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, Australia
1 shared publication
Latest Publications
- 1 November 2006
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 47 (4) , 217-230
Biologic agents in psoriasis
This paper reviews the new biologic agents that selectively block the immunologic steps implicated in the pathogenesis of psoriasis. Four strategies have been targeted: reduction of the number of pathogenic T cells; inhibition of T-cell activation and migration; modulation of the immune system; and blockage of the activity of inflammatory cytokines. There are three classes: monoclonal antibodies, fusion proteins and recombinant cytokines or growth factors. The actions, efficacy and side-effect profile of the biologic agents, alefacept, efalizumab, etanercept and infliximab, are reviewed.
- 1 November 2006
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 47 (4) , 217-230
Biologic agents in psoriasis
This paper reviews the new biologic agents that selectively block the immunologic steps implicated in the pathogenesis of psoriasis. Four strategies have been targeted: reduction of the number of pathogenic T cells; inhibition of T-cell activation and migration; modulation of the immune system; and blockage of the activity of inflammatory cytokines. There are three classes: monoclonal antibodies, fusion proteins and recombinant cytokines or growth factors. The actions, efficacy and side-effect profile of the biologic agents, alefacept, efalizumab, etanercept and infliximab, are reviewed.
- 13 July 2006
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 47 (3) , 151-159
Immunopathogenesis of psoriasis
SUMMARY: This paper reviews the pathogenesis of psoriasis, in particular, the immunological cascade in psoriasis. Psoriasis is an immune‐mediated skin disease where the T cell plays a pivotal role in the pathogenesis of the disease. The critical steps involved in the pathogenesis include Langerhans cell activation and maturation by antigens in the skin, activation of the T cell by mature Langerhans cells, differentiation and expansion of T cells within the lymph nodes, trafficking of activated T cells from the lymph node to the skin and the subsequent release of cytokines. These cytokines are responsible for epidermal and vascular hyperproliferation and pro‐inflammatory effects. Each of these steps provides an opportunity for biological agents designed to block the psoriatic immunological cascade. This paper reviews the immunopathogenesis of psoriasis. Biologic agents in psoriasis, to be published separately, reviews the new biologic therapies that aim to selectively block the immunological steps implicated in the pathogenesis of psoriasis outlined in this paper.
- 13 July 2006
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 47 (3) , 151-159
Immunopathogenesis of psoriasis
SUMMARY: This paper reviews the pathogenesis of psoriasis, in particular, the immunological cascade in psoriasis. Psoriasis is an immune‐mediated skin disease where the T cell plays a pivotal role in the pathogenesis of the disease. The critical steps involved in the pathogenesis include Langerhans cell activation and maturation by antigens in the skin, activation of the T cell by mature Langerhans cells, differentiation and expansion of T cells within the lymph nodes, trafficking of activated T cells from the lymph node to the skin and the subsequent release of cytokines. These cytokines are responsible for epidermal and vascular hyperproliferation and pro‐inflammatory effects. Each of these steps provides an opportunity for biological agents designed to block the psoriatic immunological cascade. This paper reviews the immunopathogenesis of psoriasis. Biologic agents in psoriasis, to be published separately, reviews the new biologic therapies that aim to selectively block the immunological steps implicated in the pathogenesis of psoriasis outlined in this paper.
- 30 September 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (4) , 211-220
Prurigo nodularis: A review
SUMMARY: Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology. This condition is a difficult disease to treat and causes frustration to both the patient and the treating doctor. A variety of systemic conditions have been reported to be associated with prurigo nodularis. The mechanism by which these disorders may trigger prurigo nodularis is unknown. Nerve growth factor has been implicated in the pathogenesis of prurigo nodularis. Calcitonin gene‐related peptide and substance P immunoreactive nerves are markedly increased in prurigo nodularis when compared with normal skin. These neuropeptides may mediate the cutaneous neurogenic inflammation and pruritus in prurigo nodularis. Topical or intralesional glucocorticoids are the treatment of choice. Other topical treatments such as topical vitamin D3, and topical capsaicin have also been reported to be effective. Oral treatments such as cyclosporin and thalidomide have been shown to improve both appearance of the skin and pruritus. We review the clinical features, associations, pathology, pathogenesis and treatment of prurigo nodularis.
- 30 September 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (4) , 211-220
Prurigo nodularis: A review
SUMMARY: Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology. This condition is a difficult disease to treat and causes frustration to both the patient and the treating doctor. A variety of systemic conditions have been reported to be associated with prurigo nodularis. The mechanism by which these disorders may trigger prurigo nodularis is unknown. Nerve growth factor has been implicated in the pathogenesis of prurigo nodularis. Calcitonin gene‐related peptide and substance P immunoreactive nerves are markedly increased in prurigo nodularis when compared with normal skin. These neuropeptides may mediate the cutaneous neurogenic inflammation and pruritus in prurigo nodularis. Topical or intralesional glucocorticoids are the treatment of choice. Other topical treatments such as topical vitamin D3, and topical capsaicin have also been reported to be effective. Oral treatments such as cyclosporin and thalidomide have been shown to improve both appearance of the skin and pruritus. We review the clinical features, associations, pathology, pathogenesis and treatment of prurigo nodularis.
- 7 July 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (3) , 199-201
Papillon–Lefèvre syndrome treated with acitretin
SUMMARY: A 7‐year‐old boy born to consanguineous parents had suffered from palmoplantar keratoderma and chronic gingivitis since the age of 3 months. He was diagnosed with Papillon–Lefèvre syndrome. Genetic testing confirmed that he was homozygous with a point mutation in exon 6 of the cathepsin C gene. One year after initiating treatment with acitretin 10 mg oral daily and trimethoprim‐sulfamethoxazole, the patient's skin remains almost lesion‐free, and he has new teeth that erupted during treatment and are free of periodontal disease.
- 7 July 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (3) , 199-201
Papillon–Lefèvre syndrome treated with acitretin
SUMMARY: A 7‐year‐old boy born to consanguineous parents had suffered from palmoplantar keratoderma and chronic gingivitis since the age of 3 months. He was diagnosed with Papillon–Lefèvre syndrome. Genetic testing confirmed that he was homozygous with a point mutation in exon 6 of the cathepsin C gene. One year after initiating treatment with acitretin 10 mg oral daily and trimethoprim‐sulfamethoxazole, the patient's skin remains almost lesion‐free, and he has new teeth that erupted during treatment and are free of periodontal disease.
- 7 July 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (3) , 196-198
Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy
SUMMARY: An 82‐year‐old man presented with invasive squamous cell carcinoma of the glans penis arising in erythroplasia of Queyrat. He underwent Mohs’ micrographic surgery for the invasive carcinoma. Seven weeks later, the residual erythroplasia of Queyrat was treated using photodynamic therapy. Methyl aminolevulinate cream was applied to the glans of the penis under occlusion for 3 hours and then, after local anaesthesia, irradiated with a 630‐nm red‐light‐emitting diode lamp at a dose of 37 J/cm2 for 8 min. The patient experienced some mild swelling, redness and pain, which subsided over the following 5 days. Eighteen weeks after photodynamic therapy, there had been no recurrence of the lesion, when the patient died from an unrelated cause.
- 7 July 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (3) , 196-198
Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy
SUMMARY: An 82‐year‐old man presented with invasive squamous cell carcinoma of the glans penis arising in erythroplasia of Queyrat. He underwent Mohs’ micrographic surgery for the invasive carcinoma. Seven weeks later, the residual erythroplasia of Queyrat was treated using photodynamic therapy. Methyl aminolevulinate cream was applied to the glans of the penis under occlusion for 3 hours and then, after local anaesthesia, irradiated with a 630‐nm red‐light‐emitting diode lamp at a dose of 37 J/cm2 for 8 min. The patient experienced some mild swelling, redness and pain, which subsided over the following 5 days. Eighteen weeks after photodynamic therapy, there had been no recurrence of the lesion, when the patient died from an unrelated cause.
- 13 April 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (2) , 76-79
Liposuction for axillary hyperhidrosis
SUMMARY: Excessive axillary sweating is a common problem for which many patients frequently seek dermatological advice. The removal of axillary sweat glands using liposuction with tumescent anaesthesia in an outpatient setting is a relatively short and simple procedure with few complications, as seen in this case series. We present 10 patients treated with axillary liposuction under tumescent anaesthesia. Of the 10 patients treated, four relapsed with axillary hyperhidrosis and required additional liposuction to the same area. The longest time to relapse was 15 months, with 4 months being the shortest time. Six patients have not required additional liposuction, with 7 years being the longest time of remission. The complications reported were bruising in the axillae of two patients and relapse of hyperhidrosis in four patients.
- 13 April 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (2) , 76-79
Liposuction for axillary hyperhidrosis
SUMMARY: Excessive axillary sweating is a common problem for which many patients frequently seek dermatological advice. The removal of axillary sweat glands using liposuction with tumescent anaesthesia in an outpatient setting is a relatively short and simple procedure with few complications, as seen in this case series. We present 10 patients treated with axillary liposuction under tumescent anaesthesia. Of the 10 patients treated, four relapsed with axillary hyperhidrosis and required additional liposuction to the same area. The longest time to relapse was 15 months, with 4 months being the shortest time. Six patients have not required additional liposuction, with 7 years being the longest time of remission. The complications reported were bruising in the axillae of two patients and relapse of hyperhidrosis in four patients.
- 25 January 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (1) , 42-43
Herpes zoster following cryosurgery
SUMMARY: A 56‐year‐old man developed reactivation of herpes zoster infection on his right forehead after treatment of several solar keratoses with cryosurgery. The rash was blistering and painful. Treatment with oral aciclovir was instituted and the lesions healed within 2 weeks. Known risk factors for reactivation include age and decreased immunity. Previous case reports have indicated trauma may be a risk factor in herpes zoster. We report a case of herpes zoster as a complication of cryosurgery.
- 25 January 2005
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 46 (1) , 42-43
Herpes zoster following cryosurgery
SUMMARY: A 56‐year‐old man developed reactivation of herpes zoster infection on his right forehead after treatment of several solar keratoses with cryosurgery. The rash was blistering and painful. Treatment with oral aciclovir was instituted and the lesions healed within 2 weeks. Known risk factors for reactivation include age and decreased immunity. Previous case reports have indicated trauma may be a risk factor in herpes zoster. We report a case of herpes zoster as a complication of cryosurgery.